List of Excipients in Branded Drug ELLENCE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	ELLENCE	epirubicin hydrochloride	0009-5091	HYDROCHLORIC ACID
Pharmacia & Upjohn Company LLC	ELLENCE	epirubicin hydrochloride	0009-5091	SODIUM CHLORIDE
Pharmacia & Upjohn Company LLC	ELLENCE	epirubicin hydrochloride	0009-5091	SODIUM HYDROXIDE
Pharmacia & Upjohn Company LLC	ELLENCE	epirubicin hydrochloride	0009-5091	WATER

Ellence Excipient Strategy and Commercial Opportunities: Epirubicin Injection Patent, Regulatory, and Market Analysis

Last updated: August 28, 2026

Ellence is a sterile, preservative-free epirubicin hydrochloride injection supplied at 2 mg/mL. Its formulation is intentionally simple: sodium chloride, hydrochloric acid for pH adjustment, and water for injection. The original formulation offers little composition-of-matter or excipient-based differentiation. Commercial opportunities are concentrated in ready-to-administer presentations, dose-standardized oncology bags, stability-controlled packaging, supply reliability, and workflow products rather than in new excipient chemistry.

Epirubicin is an established anthracycline used primarily in breast cancer treatment and in bladder cancer regimens in certain markets. The product faces mature generic competition, limited regulatory exclusivity, and no biosimilar exposure because epirubicin is a chemically synthesized small molecule.

What excipients are used in Ellence?

Ellence contains sodium chloride, hydrochloric acid, and water for injection. The drug product is a clear red solution with an epirubicin hydrochloride concentration of 2 mg/mL. Hydrochloric acid adjusts the formulation pH rather than acting as a therapeutic excipient. [1]

Component	Function	Commercial significance
Epirubicin hydrochloride	Active ingredient	Anthracycline cytotoxic agent
Sodium chloride	Tonicity adjustment	Conventional, low-risk parenteral excipient
Hydrochloric acid	pH adjustment	Supports formulation control and stability
Water for injection	Vehicle	Standard injectable solvent

The formulation does not rely on preservatives, surfactants, complexing agents, antioxidants, or proprietary delivery excipients. That simplicity supports generic development but limits opportunities to claim a differentiated formulation based solely on inactive ingredients.

What is the Ellence concentration and dosage form?

Ellence is supplied as a ready-to-use solution for intravenous administration at 2 mg/mL. Pfizer labeling identifies single-dose vial presentations, including 25 mg, 50 mg, 100 mg, and 200 mg strengths in certain product configurations. Product availability can vary by market and manufacturing source. [1]

The concentrated vial format is operationally familiar to oncology pharmacies but requires dose withdrawal, dilution when clinically indicated, hazardous-drug handling, and administration under institutional protocols.

How strong is the Ellence formulation patent estate?

The formulation patent estate is weak from a commercial exclusivity perspective because Ellence uses conventional excipients and an established active ingredient. Epirubicin was disclosed and commercialized decades ago, and the original U.S. approval dates to 1999. [2]

Patent or exclusivity category	Ellence position
Active-ingredient composition patent	Expired or commercially irrelevant
Original formulation patent	No meaningful remaining exclusivity identified from the public product profile
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current commercial impact identified
Orphan-drug exclusivity	Not a principal Ellence market barrier
Formulation patents	Potentially available only for new presentations or technical improvements
Method-of-use patents	Possible for narrowly defined regimens, but unlikely to block routine generic epirubicin use
Biosimilar protection	Not applicable
Generic substitution risk	High

The main patent value would come from a separately developed product with demonstrable advantages, such as improved stability, reduced preparation burden, a closed administration system, or a validated ready-to-use presentation. A simple substitution of one conventional tonicity agent for another would likely provide limited protection and weak commercial differentiation.

What is the FDA regulatory status of Ellence?

Ellence was approved by the U.S. Food and Drug Administration under NDA 050778. It is an established injectable anthracycline rather than a new molecular entity. [2]

The key FDA characteristics are:

• Active ingredient: epirubicin hydrochloride.
• Route: intravenous.
• Dosage form: injection.
• Strength: 2 mg/mL.
• Product class: cytotoxic anthracycline.
• Regulatory pathway for competitors: generally an abbreviated new drug application, provided the proposed product meets relevant sameness and bioequivalence requirements.
• Preservative status: preservative-free product profile.
• Handling: hazardous antineoplastic drug controls apply.

The FDA label contains major warnings involving cardiotoxicity, myelosuppression, extravasation, secondary malignancies, and severe tissue injury. These risks increase the value of packaging and administration systems that reduce preparation and handling errors, but they also raise the evidentiary burden for any reformulated product. [1]

What is the Orange Book status of Ellence?

Ellence is an approved small-molecule injectable product listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations framework. The principal competitive issue is generic epirubicin hydrochloride injection rather than patent-protected reference-product exclusivity. [3]

An abbreviated applicant generally must address the reference product through an ANDA pathway and certify against any relevant listed patents. Because epirubicin is an old active ingredient and the formulation is conventional, a Paragraph IV strategy would have limited value unless an active, listed patent covered a commercially important formulation or use.

When does Ellence lose exclusivity?

Ellence has already lost the exclusivity associated with its original approval. The U.S. approval occurred in 1999, and the product operates in a mature generic market. [2]

Exclusivity type	Status
New chemical entity exclusivity	Expired
Five-year NCE period	Not commercially relevant
Original formulation exclusivity	Expired or not a meaningful current barrier
Patent-based exclusivity	No major continuing barrier evident from the public product profile
Generic competition	Established or commercially feasible
Biosimilar exclusivity	Not applicable

The practical market question is therefore not when Ellence will lose exclusivity. It is whether a manufacturer can win share through supply reliability, contract pricing, dosage-form convenience, or a differentiated administration platform.

Which companies are challenging Ellence with generic epirubicin?

Generic epirubicin products have been developed or marketed by multiple pharmaceutical manufacturers across the United States, Europe, and other regulated markets. The competitive field includes large generic injectable companies and regional oncology suppliers.

The principal competitive categories are:

1. Generic epirubicin hydrochloride injection in the same 2 mg/mL concentration.
2. Hospital-distributed epirubicin products sourced through group purchasing organizations.
3. Imported or regionally authorized products in markets where Ellence is not the dominant brand.
4. Compounded or pharmacy-prepared doses, subject to applicable pharmacy and drug-quality requirements.

A definitive current company-by-company Paragraph IV table cannot be established from the product information alone. Generic presence should be evaluated through current FDA approval records, Orange Book entries, ANDA status, and litigation databases. The commercial conclusion remains clear: generic entry risk is high, and a standard vial has limited ability to maintain premium pricing.

What formulation patents could protect a new epirubicin product?

A new epirubicin product would need a technical feature that produces a measurable clinical, stability, safety, or workflow benefit. Potential patentable areas include:

Ready-to-use epirubicin infusion bags

A manufacturer could develop a premixed epirubicin solution in a compatible infusion container. The strongest claims would likely cover:

• Defined epirubicin concentration ranges.
• Specific diluents.
• Container materials.
• Light-protection conditions.
• Storage temperature and shelf life.
• Limits on degradation products.
• Administration without pharmacy dilution.

The commercial benefit is reduced compounding labor and lower occupational exposure. The technical risk is stability. Anthracycline solutions require validated controls for concentration, degradation, container compatibility, and light exposure.

Dose-banded presentations

Dose banding could support standardized oncology doses that reduce preparation time and drug waste. Protection could involve a set of fixed strengths, defined dose ranges, and a manufacturing process that maintains potency across the product shelf life.

This opportunity is stronger in health systems that use protocolized breast cancer regimens and centralized oncology pharmacy operations. It is weaker where patient-specific body-surface-area dosing remains dominant.

Closed-system administration kits

The active pharmaceutical ingredient would remain conventional, but the commercial product could combine the vial or infusion bag with a transfer device, protective connector, or administration set. The intellectual-property value would center on the device and system claims rather than on epirubicin chemistry.

A closed-system product could address:

• Hazardous-drug exposure.
• Transfer steps.
• Aerosol or leakage risk.
• Pharmacy preparation time.
• Standardized administration.

Device integration may require separate FDA and occupational-safety assessments. It also creates licensing and manufacturing complexity.

Low-sorption or light-protective containers

A new container system could claim improved recovery of epirubicin dose, reduced adsorption, or improved stability under defined storage conditions. Glass, polymer, elastomer, and overwrap selection would be central to the development program.

The claim must demonstrate a practical advantage over the reference vial. Packaging alone is unlikely to support a premium unless it improves shelf life, reduces waste, or enables a ready-to-use format.

What manufacturing and IP barriers affect epirubicin commercial entry?

Epirubicin has a relatively accessible chemical formulation but a more demanding manufacturing and handling profile.

Manufacturing barriers

The main operational barriers are:

• High-potency cytotoxic handling.
• Dedicated or segregated manufacturing controls.
• Cross-contamination prevention.
• Sterile filtration and aseptic filling.
• Container-closure integrity.
• Potency and impurity control.
• Occupational exposure controls.
• Specialized quality systems for injectable oncology products.
• Reliable sourcing of active pharmaceutical ingredient.

These barriers favor established sterile-injectable manufacturers over small firms without cytotoxic manufacturing capacity.

Intellectual-property barriers

A standard generic injection faces limited formulation IP risk. A differentiated product may face more substantial protection around:

• Premixed infusion compositions.
• Specific container systems.
• Stability-enhancing excipient combinations.
• Dose-banding methods.
• Administration devices.
• Combination products.
• Narrow method-of-use claims.

A company seeking durable protection should pursue a portfolio combining formulation, container, process, and administration-system claims. A single composition patent would be vulnerable if competitors could reproduce the same clinical use with a conventional vial.

What excipient strategy offers the best commercial opportunity?

The strongest strategy is conservative excipient selection combined with delivery-format differentiation.

Strategy	Technical risk	IP potential	Commercial value
Conventional sodium chloride solution	Low	Low	Low to moderate
Alternative tonicity agent	Moderate	Low	Low
Antioxidant-containing formulation	Moderate to high	Moderate	Uncertain
Premixed infusion bag	Moderate	Moderate to high	High
Dose-banded ready-to-use product	Moderate	Moderate	High
Lyophilized epirubicin	High	Moderate	Low unless stability improves materially
Closed-system vial or bag	Moderate	High at system level	High
Light-protective container	Low to moderate	Moderate	Moderate
Long-term room-temperature stability	High	High if demonstrated	High

Why simple excipient substitution is unlikely to work

Changing sodium chloride to another tonicity agent may produce a patentable formulation in narrow circumstances, but the market benefit would be limited unless the change improves stability, compatibility, tolerability, or shelf life. Generic injectable buyers generally prioritize supply, price, concentration, and reliability over small inactive-ingredient differences.

Adding antioxidants or chelators also creates risk. New excipients can alter impurity profiles, compatibility with infusion materials, regulatory comparability, and toxicological requirements. The burden is difficult to justify for a mature product unless the excipient enables a measurable shelf-life or packaging benefit.

How does Ellence compare with doxorubicin and liposomal doxorubicin?

Epirubicin competes with conventional doxorubicin and, in selected settings, pegylated liposomal doxorubicin. The products are not interchangeable from a clinical, regulatory, or formulation perspective.

Attribute	Ellence	Conventional doxorubicin	Pegylated liposomal doxorubicin
Active ingredient	Epirubicin	Doxorubicin	Doxorubicin in liposomes
Formulation complexity	Low	Low to moderate	High
Primary delivery form	Solution injection	Solution injection	Liposomal injection
Excipient differentiation	Limited	Limited	Substantial
Generic competition	High	High	More technically demanding
Biosimilar pathway	Not applicable	Not applicable	Complex injectable nanomedicine issues
Main commercial differentiator	Regimen preference, supply, price	Broad use, price	Pharmacokinetic and tolerability profile
Formulation IP opportunity	Moderate for new presentations	Moderate	Higher

Liposomal doxorubicin has greater formulation complexity and potentially stronger technical barriers. Ellence has a simpler development pathway but less opportunity for composition-based exclusivity.

What licensing deals could support an Ellence commercial strategy?

The most relevant licensing targets are not likely to involve epirubicin chemistry. They are more likely to involve delivery, packaging, manufacturing, and oncology-pharmacy workflow.

Potential deal structures include:

• Licensing a ready-to-use oncology infusion platform.
• Acquiring a cytotoxic sterile-fill manufacturing site.
• Partnering with a closed-system transfer-device company.
• Licensing a validated low-sorption container.
• Contract manufacturing for premixed infusion bags.
• Regional commercialization rights for hospital oncology products.
• Co-development with a group purchasing organization or specialty distributor.

A licensee should prioritize rights that cover multiple cytotoxic products. A platform usable for epirubicin, doxorubicin, cyclophosphamide, or other oncology injectables has greater value than an epirubicin-only formulation.

What generic launch scenarios exist for Ellence?

Scenario 1: Standard vial competition

This is the highest-probability scenario. Generic manufacturers compete through price, supply continuity, and contracting. Brand Ellence retains value mainly where physicians, hospitals, or procurement systems prefer the reference product.

Scenario 2: Hospital-preferred ready-to-use bags

A premixed product could gain share by reducing pharmacy labor and hazardous-drug handling. The product would require validated stability, container compatibility, and a reliable distribution model.

Scenario 3: Dose-banded oncology supply

Fixed-dose products could attract centralized oncology pharmacies. The opportunity depends on institutional protocols, reimbursement, and the ability to control inventory without increasing wastage.

Scenario 4: Closed-system product

A combined drug-device product could compete on worker safety and workflow. The value proposition would be strongest in large cancer centers and health systems with formal hazardous-drug exposure programs.

Scenario 5: Supply-constrained market entry

A manufacturer with dependable API access and sterile cytotoxic capacity could win share even without formulation innovation. Injectable oncology shortages can shift purchasing rapidly, although supply performance must be sustained over time.

What revenue exposure does Ellence create?

Pfizer does not generally report Ellence as a separately disclosed revenue line in public financial reporting. Product-level revenue, market share, and gross margin therefore cannot be reliably quantified from public corporate reporting alone.

Revenue exposure is likely shaped by:

• Generic price erosion.
• Hospital and group purchasing contracts.
• National oncology treatment volumes.
• Product shortages.
• Availability of competing epirubicin products.
• Conversion from vial to ready-to-use formats.
• Regional treatment preferences.
• Procurement preference for branded or authorized-generic supply.

The commercial ceiling for a new Ellence formulation is constrained by the mature active ingredient. A differentiated presentation may generate value through workflow savings and procurement preference, but the addressable revenue should be modeled as a hospital injectable opportunity rather than as a protected branded-drug market.

What patent litigation affects Ellence?

No major current patent litigation is evident from the established public profile of Ellence. The product’s principal legal risks are more likely to involve:

• ANDA patent certifications.
• Product liability.
• Manufacturing quality.
• Sterile injectable compliance.
• Labeling and safety communications.
• Contracting disputes.
• Shortage-related supply obligations.

A new ready-to-use product would create a more substantial litigation profile if it obtained formulation or device patents. Potential disputes could concern claim construction around concentration, storage conditions, container materials, or administration systems.

What geographic coverage matters for epirubicin?

Epirubicin is marketed across multiple regions, but regulatory and commercial conditions differ materially.

Region	Key opportunity
United States	Generic injectable supply, ready-to-use bags, pharmacy workflow
European Union	Hospital tenders, centralized procurement, regional marketing authorizations
Japan	Established anthracycline use and local regulatory requirements
China	Large oncology market, local manufacturing, tender pricing
Emerging markets	Supply reliability and affordable generic access
Middle East and Latin America	Distributor coverage and stable injectable supply

A global strategy should separate regulated-market formulation development from lower-cost regional supply. The same product may require different presentations, labeling, packaging, and stability claims across jurisdictions.

Key Takeaways

• Ellence is a 2 mg/mL epirubicin hydrochloride injection formulated with sodium chloride, hydrochloric acid, and water for injection.
• The excipient profile is conventional and provides limited standalone patent protection.
• Original regulatory exclusivity has expired, and generic competition is the central commercial risk.
• Biosimilar risk does not apply because epirubicin is a small-molecule drug.
• The strongest commercial opportunities are ready-to-use bags, dose-banded presentations, closed-system administration, and light- or container-controlled stability.
• Simple excipient substitution is unlikely to justify a premium price.
• A durable IP strategy should combine formulation, packaging, manufacturing-process, and administration-system claims.
• Product-level Ellence revenue is not separately disclosed by Pfizer, so commercial exposure must be modeled through hospital injectable demand, generic pricing, and procurement dynamics.
• No major current patent litigation is evident from the public product profile.

FAQs

Can epirubicin be developed as a preservative-containing multidose vial?

A preservative-containing multidose presentation would require new compatibility, sterility, extractables, toxicology, and stability support. It would also need to address the suitability of preservatives for a highly cytotoxic injectable. The regulatory and operational burden would likely outweigh the benefit in most oncology settings.

Is an epirubicin prefilled syringe commercially viable?

A prefilled syringe could reduce dose-preparation steps, but cytotoxic containment, dose variability, syringe-material compatibility, shipping controls, and administration practice would determine feasibility. It is more likely to fit selected fixed-dose applications than broad hospital use.

Could a new epirubicin formulation receive 505(b)(2) approval?

A materially different formulation or delivery system could potentially use a 505(b)(2) pathway if the regulatory requirements are met. The value would depend on whether the product offers a clinically or operationally meaningful advantage over approved epirubicin injections.

What stability claim would make a ready-to-use epirubicin bag attractive?

A commercially meaningful claim would combine adequate shelf life with practical storage conditions, low degradation, container compatibility, and reduced light sensitivity. The strongest value would come from eliminating pharmacy compounding while preserving predictable potency through distribution and administration.

Does epirubicin require a biosimilar development program?

No. Epirubicin hydrochloride is a chemically synthesized small molecule. Competitors generally pursue generic-drug pathways rather than biosimilar approval pathways.

References

1. U.S. Food and Drug Administration. (2023). Ellence (epirubicin hydrochloride) injection prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (1999). Ellence approval history and labeling information, NDA 050778. FDA Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Center for Drug Evaluation and Research.

4. National Institute for Occupational Safety and Health. (2023). NIOSH list of hazardous drugs in healthcare settings. Centers for Disease Control and Prevention.

5. United States Pharmacopeia. (2024). General chapter <797>: Pharmaceutical compounding - sterile preparations. United States Pharmacopeial Convention.